<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1605">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03108846</url>
  </required_header>
  <id_info>
    <org_study_id>S-CitAD</org_study_id>
    <secondary_id>R01AG052510</secondary_id>
    <nct_id>NCT03108846</nct_id>
  </id_info>
  <brief_title>Escitalopram for Agitation in Alzheimer's Disease</brief_title>
  <acronym>S-CitAD</acronym>
  <official_title>Escitalopram for Agitation in Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JHSPH Center for Clinical Trials</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>JHSPH Center for Clinical Trials</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of escitalopram for&#xD;
      agitation in Alzheimer's dementia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to examine the efficacy and safety of escitalopram as treatment for&#xD;
      agitation in Alzheimer's dementia (AD) patients. Participants with clinically significant&#xD;
      agitation, and their caregiver(s), will receive a structured psychosocial intervention.&#xD;
      Participants not showing a response three weeks later will be randomized 1:1 to escitalopram&#xD;
      (up to 15 mg/day) or a matching placebo. Participants will receive study drug for 12 weeks,&#xD;
      with in-person and remote (phone/video) visits at weeks 3, 6, 9, and 12, and with telephone&#xD;
      contacts between in-person and remote visits. Following the 12-week study treatment period,&#xD;
      participants will be followed for another 12 weeks without receiving study drug. Participants&#xD;
      who do show a response to the psychosocial intervention will not be randomized to study drug&#xD;
      but will be followed remotely for the 24-week follow-up period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 3, 2018</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Over-encapsulation</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>modified- Alzheimer's Disease Cooperative Study--Clinical Global Impression of Change (mADCS-CGIC)</measure>
    <time_frame>after 12 weeks</time_frame>
    <description>Clinical Global Impression of Change</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">392</enrollment>
  <condition>Dementia</condition>
  <arm_group>
    <arm_group_label>Escitalopram</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escitalopram up to 15mg/day taken as 1-3 capsules each containing 5mg escitalopram once per day in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1-3 capsules each containing placebo only once per day in the morning</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram</intervention_name>
    <description>5-15 mg/day (target: 15mg/day if tolerated)</description>
    <arm_group_label>Escitalopram</arm_group_label>
    <other_name>Lexapro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Masked placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>non-applicable</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          1. Alzheimer's dementia diagnosed clinically by the National Institute on Aging (NIA) and&#xD;
             the Alzheimer's Association (AA) (2011 NIA/AA criteria)&#xD;
&#xD;
          2. Mini-Mental State Examination Telephone (MMSET) score of 3-20 inclusive&#xD;
&#xD;
          3. Meets the International Psychogeriatric Association (IPA) provisional criteria for&#xD;
             agitation in cognitive disorders&#xD;
&#xD;
          4. Clinically significant agitation/aggression as assessed by the Neuropsychiatric&#xD;
             Inventory (NPI) for which either:&#xD;
&#xD;
               -  The frequency is 'Very frequently,' or&#xD;
&#xD;
               -  The frequency is 'Frequently' AND the severity is 'Moderate' or 'Marked'&#xD;
&#xD;
          5. Provision of informed consent for participation in the study by both caregiver and&#xD;
             participant (or, if participant is unable to provide informed consent, with surrogate&#xD;
             consent and participant assent)&#xD;
&#xD;
          6. Availability of a caregiver who spends at least several hours per week with the&#xD;
             participant, supervises his/her care, is willing to accompany the participant to study&#xD;
             visits, and is willing to participate in the study&#xD;
&#xD;
          7. Stable (for ≥ 7 days) dosing of antipsychotics for agitation or psychosis, if being&#xD;
             used at all&#xD;
&#xD;
          8. A medication for agitation is appropriate, in the opinion of the study physician&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          1. Has major depression, as indicated by major depressive episode (MDE) in the past 90&#xD;
             days (meeting the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition&#xD;
             (DSM-V) criteria)&#xD;
&#xD;
          2. Presence of another brain disease that fully explains the dementia, (e.g., extensive&#xD;
             brain vascular disease, Parkinson's disease, dementia with Lewy bodies, traumatic&#xD;
             brain injury, or multiple sclerosis)&#xD;
&#xD;
          3. Residence in a skilled nursing or Long-Term Acute Care (LTAC) facility&#xD;
&#xD;
          4. Contraindication to treatment with escitalopram as determined by a study physician,&#xD;
             such as recent (30 days) use of monoamine oxidase inhibitors (MAOIs) or potential&#xD;
             participant is hypersensitive to escitalopram or citalopram or any inactive&#xD;
             ingredients&#xD;
&#xD;
          5. Prior failed treatment attempt with citalopram or escitalopram for agitation after&#xD;
             adequate trial, at minimally accepted dose&#xD;
&#xD;
          6. Indication for psychiatric hospitalization or acute suicidality, in the opinion of the&#xD;
             study physician&#xD;
&#xD;
          7. Recent (&lt; 7 days) changes in antipsychotics, anticonvulsants, or psychosis (delusions&#xD;
             or hallucinations) requiring a new or change in antipsychotic treatment (in the&#xD;
             opinion of the study physician)&#xD;
&#xD;
          8. Abnormal corrected QT interval using Bazett's formula (QTcB)** as determined on&#xD;
             enrollment ECG (defined as &gt; 450 ms for men and &gt; 470 ms for women)&#xD;
&#xD;
          9. Recent (30 days) presence of severely reduced renal function (as identified by a&#xD;
             Glomerular filtration rate (GFR) clearance &lt; 30 mL/min) or reduced hepatic function&#xD;
&#xD;
         10. Current treatment (within 7 days) with any of the following:&#xD;
&#xD;
               -  antidepressants (other than trazodone, ≤ 100 mg per day at bedtime)&#xD;
&#xD;
               -  benzodiazepines (other than lorazepam), or&#xD;
&#xD;
               -  psychostimulants&#xD;
&#xD;
         11. Recent (&lt; 14 days) changes in Dextromethorphan/quinidine, prazosin, and pimavanserin&#xD;
&#xD;
         12. Recent (&lt; 14 days) use of medical marijuana&#xD;
&#xD;
         13. Current participation in a clinical trial or in any study that may add a significant&#xD;
             burden or affect neuropsychological or other study outcomes&#xD;
&#xD;
         14. Significant communicative impairments that would affect participation in a clinical&#xD;
             trial&#xD;
&#xD;
         15. Any condition that, in the opinion of the study physician, makes it medically&#xD;
             inappropriate or risky for the potential participant to enroll in the trial&#xD;
&#xD;
               -  if the QTcB is determined while the rhythm is paced, 50 ms is subtracted from the&#xD;
                  calculated value. The study cardiologist must confirm eligibility in this&#xD;
                  scenario.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>109 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Constantine Lyketsos, MD, MHS</last_name>
    <role>Study Chair</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dave Shade, JD</last_name>
    <phone>4109558175</phone>
    <email>dshade@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephan Ehrhardt, MD</last_name>
    <phone>4109558175</phone>
    <email>sehrhar6@jhu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Banner Sun Health Research Institute</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85351</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daneva MinerRose</last_name>
      <phone>623-832-5468</phone>
      <email>Daneva.MinerRose@bannerhealth.com</email>
    </contact>
    <investigator>
      <last_name>Alireza Atri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Biomedical Research Foundation</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prasad Padala</last_name>
      <phone>501-257-2537</phone>
      <email>ppadala@uams.edu</email>
    </contact>
    <contact_backup>
      <last_name>Chris Parkes</last_name>
      <phone>(501) 257-2504</phone>
      <email>christopher.parkes@va.gov</email>
    </contact_backup>
    <investigator>
      <last_name>Prasad Padala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles/VA Greater Los Angeles Healthcare System</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alex Alas</last_name>
      <phone>310-478-3711</phone>
      <email>Alexander.Alas@va.gov</email>
    </contact>
    <investigator>
      <last_name>Brandon Yarns, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Southern California Keck School of Medicine Memory and Aging Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90089</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mauricio Becerra, MD</last_name>
      <phone>323-442-7594</phone>
      <email>mjbecerr@usc.edu</email>
    </contact>
    <investigator>
      <last_name>Lon S. Schneider, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sonia Pawluczy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Miami Jewish Health Systems</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33137</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Gomez</last_name>
      <phone>305-751-8626</phone>
      <phone_ext>64101</phone_ext>
      <email>agomez@miamijewishhealth.org</email>
    </contact>
    <investigator>
      <last_name>Marc Agronin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maryland VA Health Care System</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University School of Medicine, Bayview Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Toni White</last_name>
      <phone>410-550-6486</phone>
      <email>twhite46@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Paul Rosenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Insights</name>
      <address>
        <city>Glen Burnie</city>
        <state>Maryland</state>
        <zip>20161</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Norhan Ibrahim</last_name>
      <phone>410-768-2629</phone>
      <email>ibrahim@clinicalinsights.com</email>
    </contact>
    <contact_backup>
      <last_name>Lawrence Adler</last_name>
      <email>adler@clinicalinsights.com</email>
    </contact_backup>
    <investigator>
      <last_name>Lawrence Adler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alzheimer Disease Center</name>
      <address>
        <city>Quincy</city>
        <state>Massachusetts</state>
        <zip>02169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Lou Ruvo Center for Brain Health</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Guerra</last_name>
      <phone>702-701-7893</phone>
      <email>GUERRAM@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Aaron Ritter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack Meridian Health</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lee Ifhar</last_name>
      <phone>551-996-1325</phone>
      <email>Lee.Ifhar@hmhn.org</email>
    </contact>
    <investigator>
      <last_name>Florian Thomas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Izael Nino</last_name>
      <phone>646-774-8671</phone>
      <email>izael.nino@nyspi.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Davangere P. Devanand, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14620</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Salem-Spencer, RN, MSN</last_name>
      <phone>585-602-5203</phone>
      <email>Susan_Salem-Spencer@urmc.rochester.edu</email>
    </contact>
    <investigator>
      <last_name>Anton Porsteinsson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brooke Eiginger</last_name>
      <phone>614-293-9023</phone>
      <email>Brooke.Eiginger@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Douglas Scharre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abington Neurological Associates, Ltd</name>
      <address>
        <city>Abington</city>
        <state>Pennsylvania</state>
        <zip>19001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evan Cassar</last_name>
      <phone>215-957-9250</phone>
      <email>evancassar.ana@gmail.com</email>
    </contact>
    <investigator>
      <last_name>David Weisman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alzheimer Disease Research Center; University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Henderson</last_name>
      <phone>412-692-2700</phone>
      <email>hendersonpl@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Oscar Lopez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ralph H. Johnson VA Medical Center</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Richard Freeman</last_name>
      <email>freeman@lcvresearch.org</email>
    </contact>
    <investigator>
      <last_name>Jacobo Mintzer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roper St. Francis Healthcare</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Freeman</last_name>
      <phone>843-724-2348</phone>
      <email>Richard.Freeman@rsfh.com</email>
    </contact>
    <investigator>
      <last_name>Jacobo Mintzer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor AT&amp;T Memory Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Yuglich Stultz</last_name>
      <phone>214-818-0382</phone>
      <email>sarah.yuglichstultz@bswhealth.org</email>
    </contact>
    <investigator>
      <last_name>Cindy Marshall, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eastern Virginia Medical School</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaitlin Romm</last_name>
      <phone>757-446-7406</phone>
      <email>RommKE@EVMS.EDU</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwest Clinical Research Center</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>University of Calgary and Foothills Medical Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharanjit Kaur</last_name>
      <phone>(403) 210-7737</phone>
      <email>sharanjit.kaur@ucalgary.ca</email>
    </contact>
    <contact_backup>
      <last_name>Lily Guan</last_name>
      <phone>403-210-7737</phone>
      <email>ltwguan@ucalgary.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Zahinoor Ismail, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lawson Health Research Institute/Parkwood Institute</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6C 0A7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Neuropsychopharmacology Research Group, Sunnybrook</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abby Li</last_name>
      <phone>(416) 480-6100</phone>
      <phone_ext>3185</phone_ext>
      <email>Abby.Li@sunnybrook.ca</email>
    </contact>
    <investigator>
      <last_name>Krista Lanctot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unity Health</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Komal Talib</last_name>
      <email>Komal.Talib@unityhealth.to</email>
    </contact>
    <investigator>
      <last_name>Connie Fischer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre for Addiction and Mental Health</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6J1H4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rhea Harduwar, MD</last_name>
      <phone>416-535-8501</phone>
      <phone_ext>32460</phone_ext>
      <email>Rhea.Harduwar@camh.ca</email>
    </contact>
    <investigator>
      <last_name>Tarek Rajji, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre for Memory and Aging</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Ontario Shores</name>
      <address>
        <city>Whitby</city>
        <state>Ontario</state>
        <zip>L1N 5S9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nilah Ahimsadasan</last_name>
      <phone>905-430-4055</phone>
      <phone_ext>6053</phone_ext>
      <email>ahimsadasann@ontarioshores.ca</email>
    </contact>
    <investigator>
      <last_name>Amer Burhan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 6, 2017</study_first_submitted>
  <study_first_submitted_qc>April 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2017</study_first_posted>
  <last_update_submitted>May 6, 2021</last_update_submitted>
  <last_update_submitted_qc>May 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>JHSPH Center for Clinical Trials</investigator_affiliation>
    <investigator_full_name>Dave Shade</investigator_full_name>
    <investigator_title>Director, S-CitAD Coordinating Center</investigator_title>
  </responsible_party>
  <keyword>Alzheimer's Disease</keyword>
  <keyword>Agitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Psychomotor Agitation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

